Optimization of Acute Treatment in First Episode Schizophrenia
Status:
Unknown status
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The study is a multicenter, double-blind, randomized, parallel-group study with first episode
schizophrenic patients. During a treatment phase of 8 weeks the patients are treated with
Risperidone or Haloperidol. Aim of the project is to compare the effects of the atypical
neuroleptic Risperidone with those of the conventional neuroleptic Haloperidol and to
evaluate whether the assumed advantages of atypical neuroleptics compared to conventional
neuroleptics are also present when both medications are administered in rather low daily
dosages (min. 2 mg/d; max. 8 mg/d).
Phase:
Phase 4
Details
Lead Sponsor:
Ludwig-Maximilians - University of Munich
Collaborators:
Department of Psychiatry University FU Berlin Department of Psychiatry University of Bonn German Research Network On Schizophrenia Heinrich-Heine University, Duesseldorf Janssen-Cilag Ltd. Mainz University Martin-Luther-Universität Halle-Wittenberg RWTH Aachen University Universität Duisburg-Essen University Hospital Tuebingen University of Cologne University of Göttingen University of Jena University of Mannheim University of Wuerzburg